TCGA-GU-A42Q-01A-11R-A23W-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.30091984
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- G2M_CHECKPOINT+0.520
- E2F_TARGETS+0.510
- MYC_TARGETS_V1+0.490
- MITOTIC_SPINDLE+0.410
- MTORC1_SIGNALING+0.370
- GLYCOLYSIS+0.360
- HYPOXIA+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- HEDGEHOG_SIGNALING+0.330
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.450
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_GAMMA_RESPONSE-0.390
- KRAS_SIGNALING_UP-0.280
- IL6_JAK_STAT3_SIGNALING-0.260
- INFLAMMATORY_RESPONSE-0.260
- COMPLEMENT-0.190
- IL2_STAT5_SIGNALING-0.160
- BILE_ACID_METABOLISM-0.150
- PEROXISOME-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-43-A474-01A-11R-A24H-07 | — | cohortSQ2 | 0.911 |
| 2 | TCGA-33-4586-01A-01R-1443-07 | — | cohortSQ2 | 0.889 |
| 3 | TCGA-94-A5I6-01A-21R-A27Q-07 | — | cohortSQ2 | 0.876 |
| 4 | TCGA-18-5592-01A-01R-1635-07 | — | cohortSQ2 | 0.864 |
| 5 | C3L-00081 | — | cohortSQ2 | 0.863 |
| 6 | TCGA-18-5595-01A-01R-1635-07 | — | cohortSQ2 | 0.860 |
| 7 | TCGA-21-1072-01A-01R-0692-07 | — | cohortSQ2 | 0.857 |
| 8 | SRR35579803 | — | E | 0.855 |
| 9 | TCGA-A2-A0YJ-01A-11R-A109-07 | — | E | 0.853 |
| 10 | TCGA-NK-A5CR-01A-11R-A26W-07 | — | cohortSQ2 | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.360 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |